What is the prospect of junshi biology?

Junshi Bio has a good prospect and is committed to the discovery and development of innovative drugs, as well as clinical research and development and commercialization on a global scale. The highest target price was found to be HK$ 70.67.

According to media reports, Junshi Bio was founded by Chen Bo, who resigned as executive director and general manager on 20/0/5 and chief scientist on 20/0/6. According to the resume, Chen Bo was born in 1974. In 2003, he graduated from Einstein Medical College with a doctor's degree in medicine. He has served as a professor at Fudan University, a researcher at Lilly Company and a senior researcher at stem cell therapy biopharmaceutical company.

Junshi Bio was founded in 20 12 and 12. It is an innovation-driven biopharmaceutical company, dedicated to the discovery and development of innovative drugs, as well as clinical research and development and commercialization on a global scale. The legal representative of the company is Xiong Jun, whose business scope is biomedical research and development, and provides related technology development and technical consultation.

Junshi Bio is in a leading position in the fields of tumor immunotherapy, autoimmune diseases and metabolic diseases treatment by virtue of its excellent innovative drug discovery ability, advanced biotechnology research and development, large-scale production technology in the whole industry chain and rapid expansion of the drug combination under research with huge market potential.

On June 5438+February 5, 2022, Junshi Bio announced that the company had recently received a notice from the European Medicines Agency (EMA) that triprolidine combined with cisplatin and gemcitabine was the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma.

EMA has accepted the application for marketing permission of Tereplizumab combined with paclitaxel and cisplatin for first-line treatment of unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma.